CDA | Evidence Driven
CDA | Evidence Driven

drospirenone

Details

Files
Generic Name:
drospirenone
Project Status:
Active
Therapeutic Area:
Contraceptive, oral
Manufacturer:
Duchesnay Inc.
Call for patient/clinician input open:
Brand Name:
Slynd
Project Line:
Reimbursement Review
Project Number:
SR0806-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Slynd (drospirenone) is indicated for conception control in adolescent and adult women.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Slynd (drospirenone) is indicated for conception control in adolescent and adult women.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open30-Jun-23
Call for patient/clinician input closed25-Aug-23
Clarification:

- No patient input submission received

Submission received14-Aug-23
Submission accepted30-Aug-23
Review initiated31-Aug-23
Clarification:

- Submission was not accepted for review on 28 Aug 2023

Draft CADTH review report(s) provided to sponsor for comment24-Nov-23
Deadline for sponsors comments05-Dec-23
CADTH review report(s) and responses to comments provided to sponsor12-Jan-24
Expert committee meeting (initial)24-Jan-24
Draft recommendation issued to sponsor06-Feb-24
Draft recommendation posted for stakeholder feedback15-Feb-24
End of feedback period01-Mar-24
Final recommendation issued to sponsor and drug plans18-Mar-24
Final recommendation posted04-Apr-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)02-Apr-24
CADTH review report(s) posted-

Files

Recommendation and Reasons View PDF
Last Updated : May 22, 2024